Medical Marijuana Inc. Holdings Announces Commencement of Clinical Trials for New Pharmaceutical Product
San Diego, CA (eTeligis via ACCESSWIRE) 7/30/2013 – Medical Marijuana Inc. (OTC PINK: MJNA) and CanChew Biotechnologies are pleased to inform shareholders and the general public that the CanChew Biotechnologies Board of Directors elected three new executives with clearly defined roles: Dr. George E. Anastassov, MD, DDS, Exec. MBA as Chief Executive Officer (CEO); Dr. Philip. A. Van Damme DMD, MD, PhD as Chief Medical Officer (CMO); and Lekhram Changoer, MSc BSc as Chief Technology Officer (CTO)during their annual meeting last week at the Medical Marijuana Inc. offices in San Diego, California.
These gentlemen have been with CanChew Biotechnologies since its inception. We are very excited to take our business partnership to new heights with these appointments,” said Charles Vest, Director of Communications for HempMedsPX, the marketing company for Medical Marijuana Inc. and all MJNA portfolio companies.
“The Board of Directors unanimously agreed that it was important to have a medical doctor with a business background in a CEO role for CanChew Biotechnologies. Dr. Anastassov will bring decades of medical and dental knowledge and clinical research in cranio-maxillofacial and base of the skull surgery experience to his role as Chief Executive Officer. With the inclusion of Dr. van Damme’s oral & cranio-maxillofacial surgical background and Mr. Changoer’s extensive product development, clinical research, and health care marketing experience, it’s an exciting time to be an MJNA shareholder.”
As Chief Technology Officer, Mr. Changoer will continue to oversee organizational and technical aspects of the clinical trials for CanChew Biotechnologies products, and Dr. van Damme will be spearheading the medical issues related to product developments for their patented CBD gum: CanChew. HempMedsPX will begin an aggressive marketing campaign alongside in-depth introductions to the CanChew Biotechnologies team and their MJNA counterparts.
In clinical and product development news: CanChew Biotechnologies are moving forward with MedChewRX, a combination CBD/THC gum that will be sold and marketed as a pharmaceutical drug. It’s anticipated to take approximately three years of clinical trials to get FDA (Food and Drug Administration) and EMA (European Medicines Agency) approval for MedChewRX. The board unanimously voted to proceed with clinical trials and possible eventual out-licensing, and resolved to accept full funding with a budget approved by the Board of Directors. At that time, Mr. Changoer will initiate MedChewRX gum production. The clinical indication for this THC/CBD gum will be for pain; as of this press release, MedChewRX will contain 5mg of CBD and 5mg of THC.
Global market opportunities in the CBD/THC functional gum continue to expand. Canada has federal licensing for the production of cannabis and the importation of cannabis; Israel and the Czech Republic are allowing importation; and Israel can export THC because of existing cannabis licensing. CanChew Biotechnologies will aggressively seek appropriate licensing partners in these and other countries.
The new executive officers will be the contact points for interviews and clinical information about CanChew and MedChewRX. Full biographies of the new executive team may be found at CanChewBiotech.com.
According to the US government, every product derived from cannabis is categorized as marijuana including hemp. We, therefore, use the word “marijuana” as an all-encompassing term to cover cannabis, medical marijuana, marijuana and hemp. We believe that “cannabis” should be the standard term used for all medical products; as the industry matures, we will be phasing out the words “medical marijuana” and “marijuana” from the company’s vocabulary.
About CanChew Biotechnologies
CanChew Biotechnologies focuses on the treatment of pain and other medical disorders with the application of chewing gum-based cannabis/cannabinoid medical products.
The company is focused on the R&D and execution of their clinical development plan and the out-licensing of their technology. Clinical development focuses on the R&D of the formulation, production and the development of chewing gum-based products for the treatment of issues like pain, nausea and vomiting, anorexia, spasticity and various other medical issues. For more information on the company, visit CanChewBiotech.com.
HempMedsPX is the master distributor and contracted marketing company for the CannaVest Corp. and Medical Marijuana, Inc. (OTC Pink: MJNA) portfolio of products, including their revolutionary hemp-based CBD products. HempMedsPX offers mainstream marketing, sales, customer service, and logistics for the cannabis industry. In addition to handling sales and distribution, HempMedsPX is the communication hub for the Medical Marijuana Inc. portfolio of companies.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally friendly, economically sustainable businesses, while increasing shareholder value. For more information, please visit the company’s website at:https://www.medicalmarijuanainc.com/.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
Medical Marijuana, Inc., and HempMedsPX do not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell and distribute hemp-based products and are involved with Federally Legal Distribution of Medical Marijuana based products within certain international markets.
For further information regarding HempMedsPX
Investor relations contact:
Stuart T. Smith
Medical Marijuana, Inc.
Source: Accesswire (July 30, 2013 – 9:05 AM EDT)
News by QuoteMedia